DEADLINE TODAY: Kaskela Law Alerts Solid Biosciences, Inc. Investors of Important Deadline

RADNOR, Pa.--()--Kaskela Law LLC alerts Solid Biosciences, Inc. (NASDAQ: SLDB) (“Solid Biosciences” or the “Company”) investors that a class action lawsuit has been filed on behalf of investors who purchased or acquired Solid Biosciences common stock between January 25, 2018 and March 14, 2018, inclusive (the “Class Period”).

FINAL DEADLINE ALERT: Investors who purchased or acquired Solid Biosciences common stock during the Class Period may, no later than May 29, 2018, seek to be designated as a lead plaintiff representative of the investor class.

Investors are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq.) at (484) 258 – 1585 or (888) 715 – 1740 to discuss their legal rights and options with respect to this action and/or visit www.kaskelalaw.com/case/solid-biosciences-inc/ to submit their information.

On or around January 25, 2018, Solid Biosciences completed an initial public offering (“IPO”) of its common stock, selling 7,000,000 shares of stock to investors at $16.00 per share.

On March 14, 2018, Solid Biosciences disclosed that the U.S. Food and Drug Administration had placed a clinical hold on its SGT-001 Phase I/II clinical trial, IGNITE DMD. Following this news, shares of Solid Biosciences’ common stock fell $16.99 per share, or over 60%, to close on March 15, 2018 at $9.32.

The shareholder class action complaint alleges that Solid Biosciences and certain other defendants made a series of false and misleading statements and/or failed to disclose to investors that: (i) Solid Biosciences’ lead drug candidate, SGT-001, had a high likelihood of causing adverse events in patients; and (ii) Solid Biosciences had misled investors regarding the toxicity of SGT-001. The complaint further alleges that, as a result of the foregoing, investors purchased Solid Biosciences’ common stock at artificially inflated prices during the Class Period and sustained significant investment losses following the Company’s March 14, 2018 disclosures.

Investors are encouraged to contact Kaskela Law LLC to discuss their legal rights and options with respect to this action and/or visit www.kaskelalaw.com/case/solid-biosciences-inc/ to submit their information. Kaskela Law LLC exclusively prosecutes shareholder actions in state and federal courts throughout the country on behalf of investors. For additional information about Kaskela Law LLC please visit www.kaskelalaw.com.

Contacts

KASKELA LAW LLC
D. Seamus Kaskela, Esq.
201 King of Prussia Road
Suite 650
Radnor, PA 19087
484-258–1585
888-715–1740
skaskela@kaskelalaw.com
www.kaskelalaw.com

Contacts

KASKELA LAW LLC
D. Seamus Kaskela, Esq.
201 King of Prussia Road
Suite 650
Radnor, PA 19087
484-258–1585
888-715–1740
skaskela@kaskelalaw.com
www.kaskelalaw.com